Authors
Lars Lannfelt, Kaj Blennow, Henrik Zetterberg, Stellan Batsman, David Ames, John Harrison, Colin L Masters, Steve Targum, Ashley I Bush, Ross Murdoch, Janet Wilson, Craig W Ritchie
Publication date
2008/9/1
Journal
The Lancet Neurology
Volume
7
Issue
9
Pages
779-786
Publisher
Elsevier
Description
Background
PBT2 is a metal-protein attenuating compound (MPAC) that affects the Cu2+-mediated and Zn2+-mediated toxic oligomerisation of Aβ seen in Alzheimer's disease (AD). Strong preclinical efficacy data and the completion of early, clinical safety studies have preceded this phase IIa study, the aim of which was to assess the effects of PBT2 on safety, efficacy, and biomarkers of AD.
Methods
Between December 6, 2006, and September 21, 2007, community-dwelling patients over age 55 years were recruited to this 12-week, double-blind, randomised trial of PBT2. Patients were randomly allocated to receive 50 mg PBT2, 250 mg PBT2, or placebo. Inclusion criteria were early AD (mini-mental state examination [MMSE] score between 20 and 26 points or Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) score between 10 and 25 points), taking a stable dose of acetylcholinesterase …
Total citations
Scholar articles
L Lannfelt, K Blennow, H Zetterberg, S Batsman… - The Lancet Neurology, 2008